Lilly Adds To Diabetes Pipeline With Protomer Buyout

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

After investing in the California biotech, Lilly buys the company in search of safer insulin products. The pharma sees these candidates as pairing with tirzepatide to improve diabetes therapy overall.

Insulin ampoule and a syringe isolated against white background
With its buyout of Protomer, Lilly hopes it can develop a safer, more efficacious insulin

Looking to add to its already substantial diabetes portfolio, Eli Lilly and Company announced on 14 July that it will buy Protomer Technologies, which is working on glucose-sensitive insulins, less than a year after making an equity investment in the Pasadena, CA-based biotech. No specific financial terms were disclosed, but Lilly said Protomer shareholders could realize more than $1bn from the transaction if specified development and commercial milestones are achieved.

Protomer announced an equity financing in November from the Juvenile Diabetes Research Foundation, which followed Lilly’s investment that gave the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.